WhiteBook2_Part2 - 48

Appendix
Unmasking insulin resistance triggering mechanisms using
microphysiological two-organ systems as in vitro disease models of
metabolic syndrome and non-alcoholic fatty liver disease
Unravelling the heterogeneity and functions of hepatic myeloid cells in
Non-Alcoholic Fatty Liver Disease
Using Bariatric Surgery to Discover Weight-Loss Independent
Mechanisms Leading to the Reversal of Fatty Liver Disease
Validation and Molecular Characterization of Novel Glucagon-Thyroid
Hormone Conjugates for the Efficient Management of Dyslipidemia and
Fatty Liver Disease
Validation of a novel class of cyclophilin inhibitors for the treatment of
non-alcoholic steatohepatitis
Beating Goliath: Generation of Novel, Integrated and Internationally
Harmonised Approaches for Testing Metabolism Disrupting Compounds
Characterization of Key Epigenetic Targets in Hepatic Fibrosis and
Hepatocellular Carcinoma Development. Generation of New Antifibrotic
and Antitumoral Drugs.
Controlled Organoids transplantation as enabler for regenerative
medicine translation
Decompensated Cirrhosis: Identification of New Combinatorial Therapies
Based on Systems Approaches
Development of a cell-based system for high-throughput screening of
antifibrotics
Development of DIALIVE, a novel Liver Dialysis Device for the treatment
of patients with Acute on Chronic Liver Failure (ACLF)
Diagnosis and Exclusion of Drug-Induced Liver Injury by using Patient
Blood Samples (DILITEST)
Engineering the 3D Niche to enHANCE functionality of hepatocytes
derived from human iPSCs
Ex vivo Re-vascularization in Porcine Liver Bioengineering - A Critical First
Step Towards Effective Transplantation of Bioengineered Livers
Hepatocytes-Like Microreactors for Liver Tissue Engineering
Integrated Tissue Slice Culture and NMR Metabolomics - A Novel
Approach Towards Systemic Understanding of Liver Function and Disease
Live, In vivo Visualisation of liver Regeneration in Zebrafish After
Photoablation of hepatocytes
MICROBiome-based biomarkers to PREDICT decompensation of liver
cirrhosis and treatment response
Mucus-Penetrating Microbiota: Characterization, Mechanism and
Therapeutic in Metabolic Disease
Non-Invasive Quantitative Magnetic Resonance for Obese Children - the
Paediatric LiverMultiScan Test
Non-invasive rapid assessment of chronic liver disease using Magnetic
Resonance Imaging with LiverMultiScan
Novel Treatment of Acute On Chronic Liver Failure Using Synergistic
Action of G-CSF and TAK-242
Pannexin1 nanobodies for the clinical treatment of liver disease
Production of next generation modulators of pannexins and connexins as
novel therapeutics in the treatment of inflammatory cardiovascular,
hepatic and joint diseases
Regeneration and zonation by ZEB2 of Liver Endothelium
Screening for liver fibrosis - population-based study across European
countries
White Book 2: Part 2
162806.4
1500000
1499354
171460.8
150000
6761833.75
170121.6
6301156.25
6000000
195454.8
6478737.5
50000
183454.8
158121.6
1992289
3138432.5
200194.8
15000000
1850000
50000
3460486.5
5999999
150000
3503628.75
160800
5996481.25
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
Chronic liver
diseases
45
Non-alcoholic
fatty liver
disease
Non-alcoholic
fatty liver
disease
Non-alcoholic
fatty liver
disease
Non-alcoholic
fatty liver
disease
Non-alcoholic
fatty liver
disease
WhiteBook2_Part2

Table of Contents for the Digital Edition of WhiteBook2_Part2
